Your browser is no longer supported. Please, upgrade your browser.
AIM AIM ImmunoTech Inc. daily Stock Chart
AIM ImmunoTech Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own1.40% Shs Outstand17.49M Perf Week6.40%
Market Cap69.35M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float26.07M Perf Month31.68%
Income-10.00M PEG- EPS next Q-0.10 Inst Own1.90% Short Float5.28% Perf Quarter15.15%
Sales0.20M P/S346.73 EPS this Y73.20% Inst Trans-4.25% Short Ratio0.18 Perf Half Y454.98%
Book/sh1.96 P/B1.36 EPS next Y9.80% ROA-40.30% Target Price- Perf Year-42.86%
Cash/sh1.08 P/C2.47 EPS next 5Y25.00% ROE-61.50% 52W Range0.38 - 7.50 Perf YTD388.97%
Dividend- P/FCF- EPS past 5Y44.30% ROI-63.20% 52W High-64.53% Beta-0.95
Dividend %- Quick Ratio42.30 Sales past 5Y-6.60% Gross Margin- 52W Low598.16% ATR0.27
Employees31 Current Ratio42.30 Sales Q/Q- Oper. Margin- RSI (14)54.58 Volatility11.19% 11.33%
OptionableNo Debt/Eq0.19 EPS Q/Q92.50% Profit Margin- Rel Volume0.58 Prev Close2.52
ShortableYes LT Debt/Eq0.18 Earnings- Payout- Avg Volume7.51M Price2.66
Recom2.00 SMA208.66% SMA5012.44% SMA20085.87% Volume4,373,471 Change5.56%
May-14-20 06:50AM  
Apr-29-20 06:30AM  
Apr-20-20 06:30AM  
Apr-06-20 06:30PM  
Mar-31-20 06:45AM  
Mar-26-20 08:00AM  
Mar-09-20 06:30AM  
Mar-08-20 11:34AM  
Feb-27-20 06:30AM  
Feb-18-20 06:30AM  
Feb-12-20 06:30AM  
Feb-11-20 06:30AM  
Feb-05-20 06:30AM  
Jan-16-20 05:27AM  
Dec-11-19 12:20PM  
Dec-04-19 06:30AM  
Nov-15-19 10:25AM  
Oct-23-19 06:30AM  
Oct-07-19 06:30AM  
Sep-25-19 09:50AM  
Sep-24-19 06:30AM  
Sep-19-19 08:43AM  
Sep-16-19 06:50AM  
Sep-13-19 06:50AM  
Sep-10-19 07:30AM  
Sep-09-19 07:45AM  
Sep-06-19 06:30AM  
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.